Published in Am J Respir Crit Care Med on May 28, 2003
PROOF-Registry New and Extended Belgium -Luxembourg (PROOF-NEXT) | NCT03732859
Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 2.40
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Idiopathic pulmonary fibrosis. Orphanet J Rare Dis (2008) 2.34
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 2.17
Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med (2007) 2.00
Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med (2013) 1.89
Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med (2013) 1.81
Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 1.80
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2014) 1.73
Rheumatoid lung disease. Proc Am Thorac Soc (2007) 1.55
CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One (2010) 1.53
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med (2015) 1.52
Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation. Thorax (2007) 1.51
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest (2009) 1.50
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax (2009) 1.46
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology (2011) 1.32
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J (2010) 1.26
Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest (2014) 1.25
Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. CMAJ (2004) 1.21
Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant (2006) 1.09
Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med (2011) 1.09
The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One (2012) 1.07
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res (2011) 1.06
The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 1.04
Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung (2010) 1.04
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest (2009) 1.03
The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One (2011) 1.02
Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 1.01
Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol (2004) 1.01
Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol (2014) 0.94
Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med (2010) 0.93
Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol (2012) 0.87
Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging (2009) 0.87
Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis. Histopathology (2012) 0.86
Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. PLoS One (2012) 0.86
Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest (2016) 0.86
Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung (2010) 0.86
CD8+ T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis. J Inflamm (Lond) (2007) 0.85
The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res (2013) 0.85
The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol (2013) 0.85
High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res (2014) 0.84
Modulation of lung inflammation by the Epstein-Barr virus protein Zta. Am J Physiol Lung Cell Mol Physiol (2010) 0.84
Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis. Clin Med Insights Circ Respir Pulm Med (2015) 0.84
Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. Physiol Rev (2016) 0.84
The value of CT for disease detection and prognosis determination in combined pulmonary fibrosis and emphysema (CPFE). PLoS One (2014) 0.84
Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. Trans Am Clin Climatol Assoc (2004) 0.84
Severity classification for idiopathic pulmonary fibrosis by using fuzzy logic. Clinics (Sao Paulo) (2011) 0.83
Diagnosis and management of interstitial lung disease. Transl Respir Med (2014) 0.83
Idiopathic pulmonary fibrosis: early detection and referral. Respir Med (2014) 0.82
Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction. Int J Chron Obstruct Pulmon Dis (2014) 0.81
Dihydroartemisinin supresses inflammation and fibrosis in bleomycine-induced pulmonary fibrosis in rats. Int J Clin Exp Pathol (2015) 0.81
Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis. QJM (2014) 0.80
Idiopathic Pulmonary Fibrosis: Adaptive Multiple Features Method Fibrosis Association with Outcomes. Am J Respir Crit Care Med (2016) 0.79
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence (2014) 0.79
Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis. BMC Pulm Med (2015) 0.79
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest (2015) 0.79
Mononuclear phagocytes and airway epithelial cells: novel sources of matrix metalloproteinase-8 (MMP-8) in patients with idiopathic pulmonary fibrosis. PLoS One (2014) 0.79
Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis. Adv Ther (2015) 0.79
Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability. BMC Pulm Med (2014) 0.79
Clinical predictors of survival in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul) (2012) 0.79
Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis. Can Respir J (2014) 0.78
The Role of Cardiopulmonary Exercise Test in IPF Prognosis. Pulm Med (2013) 0.78
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.77
Do we need exercise tests to detect gas exchange impairment in fibrotic idiopathic interstitial pneumonias? Pulm Med (2012) 0.77
Medical Research Council dyspnea scale does not relate to fibroblast foci profusion in IPF. Diagn Pathol (2011) 0.77
Annual Change in Pulmonary Function and Clinical Characteristics of Combined Pulmonary Fibrosis and Emphysema and Idiopathic Pulmonary Fibrosis: Over a 3-Year Follow-up. Tuberc Respir Dis (Seoul) (2014) 0.76
Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med (2014) 0.76
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J (2011) 0.76
Prognosis of nonspecific interstitial pneumonia correlates with perivascular CD4+ T lymphocyte infiltration of the lung. BMC Pulm Med (2015) 0.75
The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial. BMC Pulm Med (2013) 0.75
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
[(18)F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res (2017) 0.75
Severity of lung fibrosis affects early surgical outcomes of lung cancer among patients with combined pulmonary fibrosis and emphysema. Medicine (Baltimore) (2016) 0.75
Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis. Int J Clin Exp Med (2014) 0.75
Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis (2016) 0.75
Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis. J Clin Med (2016) 0.75
Effects of leflunomide on inflamation and fibrosis in bleomycine induced pulmonary fibrosis in wistar albino rats. J Thorac Dis (2013) 0.75
The St. George's Respiratory Questionnaire as a prognostic factor in IPF. Respir Res (2017) 0.75
Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease? BMC Pulm Med (2017) 0.75
Clinical impact of high-attenuation and cystic areas on computed tomography in fibrotic idiopathic interstitial pneumonias. BMC Pulm Med (2015) 0.75
Prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2004) 0.75
Developmental Reprogramming in Mesenchymal Stromal Cells of Human Subjects with Idiopathic Pulmonary Fibrosis. Sci Rep (2016) 0.75
Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema. Int J Clin Exp Med (2015) 0.75
A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study. Eur Clin Respir J (2016) 0.75
The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med (2015) 0.75
The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One (2017) 0.75
Comparisons of Prognosis between Surgically and Clinically Diagnosed Idiopathic Pulmonary Fibrosis Using Gap Model: A Korean National Cohort Study. Medicine (Baltimore) (2016) 0.75
Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis. Respir Med (2016) 0.75
Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med (2015) 0.75
Six Minute Walk Test: A Tool for Predicting Mortality in Chronic Pulmonary Diseases. J Clin Diagn Res (2017) 0.75
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res (2017) 0.75
Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med (2017) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med (2010) 4.85
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation (2006) 3.99
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J (2013) 2.92
Diffuse alveolar hemorrhage. Chest (2010) 2.90
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol (2013) 2.74
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med (2007) 2.69
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med (2007) 2.66
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med (2011) 2.62
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62
Calcium deposition with or without bone formation in the lung. Am J Respir Crit Care Med (2002) 2.57
Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J (2012) 2.57
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54
A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med (2012) 2.54
Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51
Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.50
Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol (2002) 2.43
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 2.40
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med (2006) 2.34
Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.32
MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med (2013) 2.31
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest (2002) 2.19
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest (2003) 2.16
Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2010) 2.03
Clinical problem-solving. Anchors away. N Engl J Med (2007) 2.02
Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. Chest (2004) 2.00
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med (2007) 1.94
High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med (2005) 1.90
Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One (2007) 1.88
Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest (2011) 1.85
A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology (2010) 1.80
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2014) 1.80
Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med (2012) 1.79
The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One (2013) 1.78
Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax (2013) 1.77
Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest (2006) 1.76
Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2002) 1.76
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med (2013) 1.69
Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest (2007) 1.66
Diffuse alveolar hemorrhage. Clin Chest Med (2004) 1.66
Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest (2008) 1.65
Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 1.63
Idiopathic interstitial pneumonias: CT features. Radiology (2005) 1.61
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest (2005) 1.60
Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology (2013) 1.57
Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest (2009) 1.56
Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One (2009) 1.56
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest (2007) 1.53